Moderna stock: opportunities and challenges.MRNAUSDTPERP PERPETUAL MIX CONTRACTBITGET:MRNAUSDT.PduydaocoinModerna (MRNA) stock is trading in the $145–$154 range, staging a strong recovery driven by breakthrough cancer vaccine trial results. - Growth drivers: + Cancer vaccine breakthrough: The stock surged significantly (jumping 177% in mid-August 2026) after Phase 3 trial results for its mRNA melanoma vaccine (developed in partnership with Merck) showed highly positive signals. + Product portfolio expansion: mRNA technology is extending beyond COVID-19 into treatments for other respiratory diseases and personalized cancer therapies, helping the company regain its long-term growth outlook. - Key resistance level: $158.50 – $160.00 (the recently established peak), where short-term profit-taking pressure intensifies. - Key support level: $140.00 – $143.50 (a zone where recent opening prices and short-term moving averages converge), serving as the first line of defense in the event of a correction. - Trading strategy: + Buy (Long): Look to buy when the price pulls back to the $140 – $143 support zone and shows signs of recovery (e.g., rising volume). Cut losses if the price drops below $131. + Sell (Short/Take Profit): Take partial profits as the price approaches the $158 – $160 resistance zone, given the risk of short-term overbought conditions. Bitget allows traders to invest in an entire basket of stocks with a single tap, providing exposure to multiple related companies rather than focusing on just one. Do you prefer a buy or sell strategy for MRNA? Let's share our insights.